{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:05:29Z","timestamp":1789560329144,"version":"build-2803163510"},"reference-count":61,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":645,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:p>Ceftaroline is a novel, broad\u2010spectrum, advanced\u2010generation cephalosporin whose action is mediated by binding to penicillin\u2010binding proteins in bacteria, consistent with other \u03b2\u2010lactam antibiotics. Ceftaroline is distinct in that it has antimicrobial activity against multidrug\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (including methicillin\u2010resistant <jats:italic>S. aureus<\/jats:italic>, vancomycin\u2010intermediate <jats:italic>S. aureus<\/jats:italic> [VISA], heteroresistant VISA, and vancomycin\u2010resistant <jats:italic>S. aureus), Streptococcus pneumonia<\/jats:italic> (including drug\u2010resistant strains), and respiratory gram\u2010negative pathogens such as <jats:italic>Moraxella catarrhalis<\/jats:italic> and <jats:italic>Haemophilus influenzae<\/jats:italic> (including \u03b2\u2010lactamase\u2010positive strains). Development of resistance to ceftaroline occurs rarely in gram\u2010positive bacteria and at a similar rate to that of other oxyimino\u2010cephalosporins in gram\u2010negative bacteria. The inactive prodrug, ceftaroline fosamil, is administered by intravenous infusion and rapidly undergoes biotransformation to ceftaroline. Ceftaroline then follows a two\u2010compartment pharmacokinetic model and is eliminated primarily by renal excretion, with a half\u2010life of approximately 3 hours. Similar to other cephalosporins, time above the minimum inhibitory concentration is the pharmacodynamic parameter that best predicts efficacy for ceftaroline. Ceftaroline 600 mg intravenously every 12 hours has been shown to have similar efficacy to vancomycin plus aztreonam for the treatment of complicated skin and skin structure infections and to ceftriaxone for the treatment of community\u2010acquired bacterial pneumonia in phase III clinical trials. Ceftaroline displayed a safety profile similar to that of other cephalosporins in clinical trials. Dosage adjustment is required for moderate renal impairment and for patients receiving hemodialysis. Ceftaroline breakpoints have been proposed but not confirmed. Ceftaroline is a renally excreted broad\u2010spectrum cephalosporin that is clinically effective for the treatment of complicated skin and skin structure infections and community\u2010acquired bacterial pneumonia, and it has distinctive activity against some difficult\u2010to\u2010treat multidrug\u2010resistant gram\u2010positive organisms.<\/jats:p>","DOI":"10.1592\/phco.30.4.375","type":"journal-article","created":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T13:33:10Z","timestamp":1269437590000},"page":"375-389","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Ceftaroline: A New Cephalosporin with Activity Against Resistant Gram\u2010Positive Pathogens"],"prefix":"10.1002","volume":"30","author":[{"given":"Molly E.","family":"Steed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/519473"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/499367"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/533592"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/595857"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1508.081187"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn538"},{"key":"e_1_2_1_8_2","unstructured":"JacobsMR BajaksouzianS. WindauA. et al.Activity of ceftaroline against emerging serotypes ofStreptococcus pneumoniae.Poster presentation at 49th annual interscience conference on antimicrobial agents and chemotherapy San Francisco CA September 1215 2009."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/518452"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00113-08"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/524667"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00939-06"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.19.2138"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0896(03)00126-3"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.56.1406"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja8029448"},{"key":"e_1_2_1_18_2","unstructured":"MoisanHPM MalouinF.Binding of ceftaroline (CPT) to penicillin\u2010binding proteins (PBPs) ofStreptococcus pneumoniae(SPN) and methicillin\u2010resistantStaphylococcus aureus(MRSA). Poster presentation at 48th annual interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3501-3512.2005"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00149-08"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.12.005"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","unstructured":"SaderHS JonesRN.Antimicrobial activity of ceftaroline tested against contemporary (2008) bacteria isolated from community\u2010acquired respiratory tract infections (CARTI) including oxacillin\u2010 (methicillin\u2010) resistantStaphylococcus aureus.Poster presentation at theStaphylococcussymposium Honolulu HI March 1114 2009.","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A5949"},{"key":"e_1_2_1_23_2","unstructured":"JonesRN FritscheTR SaderHS.Ceftaroline activity against organisms causing skin and skin\u2010structure infections (SSSI) isolated in U.S. and European medical centers in 2008. Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01351-07"},{"key":"e_1_2_1_25_2","unstructured":"SaravolatzLD PawlakJ. JohnsonL.In vitro activity of ceftaroline agains CA\u2010MRSA VISA VRSA and daptomycin\u2010nonsusceptibleStaphylococcus aureus(DNSSA). Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00712-08"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01324-08"},{"key":"e_1_2_1_28_2","unstructured":"PatelSN McGeerA. GreenK. Pong\u2010PorterS. LowDE.Activities of ceftaroline ceftibiprole and cethromycin against multi\u2010drug resistant (MDR)Streptococcus pneumoniaeisolates from Canadian bacterial surveillance network (CBSN). Poster presentation at 48th annual interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_29_2","unstructured":"BarryPM LendermanCJ MelendezJH et al.In vitro activity of ceftaroline (CPT) against recent U.S. isolates ofNeisseria gonorrhoeae.Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm150"},{"key":"e_1_2_1_31_2","unstructured":"MushtaqS. LivermoreDM.AmpC induction by ceftaroline. Poster presentation at 49th annual interscience conference on antimicrobial agents and chemotherapy San Francisco CA September 1215 2009."},{"key":"e_1_2_1_32_2","unstructured":"HinshawRR SchaadtRD MurrayB. et al.Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline. Poster presentation at the 48th inter\u2010science conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_33_2","unstructured":"SchaadtRD SweeneyDA BiekD. ZurenkoGE.In vitro evaluation of the antibacterial activity of ceftaroline in combination with other antibacterial agents. Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy Chicago IL September 1720 2007."},{"key":"e_1_2_1_34_2","unstructured":"VidaillacC. LeonardSN RybakM.In vitro activity and aminoglycoside synergy of ceftaroline (CPT) against clinical isolates of hospital\u2010acquired (HA) methicillin\u2010resistantStaphylococcus aureus(MRSA). Poster presentation at 48th annual interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01452-08"},{"key":"e_1_2_1_36_2","unstructured":"CitronDM GoldsteinEJC.Effects of in vitro test method variables on ceftaroline activity aerobic gram\u2010positive and gram\u2010negative pathogens. Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki362"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01021-08"},{"key":"e_1_2_1_39_2","unstructured":"BrownSD TraczewskiMM.Ceftaroline: quality control limits for minimum inhibitory concentration (MIC) and disk diffusion susceptibility testing. Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy Chicago IL September 1720 2007."},{"key":"e_1_2_1_40_2","unstructured":"BrownSD TraczewskiMM.Ceftaroline: in vitro potency spectrum of activity MIC and disk diffusion breakpoints. Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy Chicago IL September 1720 2007."},{"key":"e_1_2_1_41_2","unstructured":"EngelhardtA. YusofA. HoP. SjostromK. JohanssonC.Comparative evaluation of ceftaroline MIC testing with Etest and CLSI broth microdilution methods. Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_42_2","unstructured":"GeJY HubbelA.In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI\u20100903M). Poster presentation at the 46th interscience conference on antimicrobial agents and chemotherapy San Francisco CA September 2730 2006."},{"key":"e_1_2_1_43_2","unstructured":"GeJY RedmanR. FlorenL. LiaoS. WiklerM.Single\u2010dose pharmacokinetics (PK) of ceftaroline (PPI\u20100903) in healthy subjects. Poster presentation at the 46th interscience conference on antimicrobial agents and chemotherapy San Francisco CA September 2730 2006."},{"key":"e_1_2_1_44_2","unstructured":"GeJY ThyeDA LiaoS. TalbotGH.Pharmacokinetics (PK) of ceftaroline (PPI\u20100903) in subjects with mild or moderate renal impairment (RI). Poster presentation at the 46th interscience conference on antimicrobial agents and chemotherapy San Francisco CA September 2730 2006."},{"key":"e_1_2_1_45_2","unstructured":"GeJY RedmanR. FlorenL. LiaoS. WiklerM.The pharmacokinetics (PK) and safety of ceftaroline (PPI\u20100903) in healthy subjects receiving mulitple\u2010dose intravenous (IV) infusions. Poster presentation at the 46th interscience conference on antimicrobial agents and chemotherapy San Francisco CA September 2730 2006."},{"key":"e_1_2_1_46_2","unstructured":"GeJY LiaoS. TalbotGH.Population pharmacokinetics (PK) analysis of ceftaroline (CPT) in volunteers and patients with complicated skin and skin structure infections (cSSSI). Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy Chicago IL September 1720 2007."},{"key":"e_1_2_1_47_2","unstructured":"RiccobeneT. JakateA. RankD. ThyeDA.An open\u2010label pharmacokinetic safety and tolerability study of single\u2010dose intravenous ceftaroline in subjects with end\u2010stage renal disease on intermittent haemodialysis. Poster presentation at the European congress of clinical microbiology and infectious diseases Helsinki Finland May 1619 2009."},{"key":"e_1_2_1_48_2","unstructured":"GeJY MaynardD. RickertDE.Comparative pharmacokinetics (PK) of ceftaroline (CPT) in rats rabbits and monkeys following a single intramuscular (IM) or intravenous (IV) injection. Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_49_2","unstructured":"RiccobeneT. FangE. ThyeDA.A single\u2010 and multiple\u2010dose study to determine the safety tolerability and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects. Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1376-1383.2006"},{"key":"e_1_2_1_51_2","unstructured":"GeJY LiaoS. ThyeDA TalbotGH.Ceftaroline (CPT) dose adjustment recommendations for subjects with mild or moderate renal impairment (RI). Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy Chicago IL September 1720 2007."},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-004-0309-3"},{"key":"e_1_2_1_53_2","unstructured":"XiongYQ LiY. AbdelsayedGA BiekD. BayerAS.Real\u2010time evaluation of ceftaroline a new cephalosporin vs vancomycin & daptomycin in a rat S.aureusendocarditis model using in vivo bioluminescent imaging. Poster presentation at the 47th interscience conference on antimicrobial agents and chemotherapy Chicago IL September 1720 2007."},{"key":"e_1_2_1_54_2","unstructured":"JacquelineC. AmadorG. BatardE. et al.Assessment of the in vivo activity of ceftaroline (CPT) against vancomycin\u2010susceptible and \u2010resistantEnterococcus faecalis(EF) strains in a rabbit endocarditis model (REM): comparison with linezolid (LZO) and vancomycin (VAN). Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_55_2","unstructured":"JacquelineC. CaillonJ. LeMabecqueV. et al.Evaluation of the efficacy of intramuscular (IM) administration of ceftaroline (CPT) against a methicillin\u2010resistantStaphylococcus aureus(MRSA) strain in a rabbit endocarditis model (REM). Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-06"},{"key":"e_1_2_1_57_2","unstructured":"JacquelineC. CaillonJ. AmadorG. et al.In vivo assessment of the activity of ceftaroline linezolid and vancomycin in a rabbit osteomyelitis experimental model due to MRSA and GISA. Poster presentation at the American College of Clinical Pharmacy spring practice and research forum Phoenix AZ April 59 2008."},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00590-07"},{"key":"e_1_2_1_59_2","unstructured":"WilcoxM. CoreyGR TalbotGH BaculikT. ThyeDA.CANVAS\u20102: randomized double\u2010blinded phase 3 study (P903\u201307) of the efficacy and safety of ceftaroline vs vancomycin plus aztreonam in complicated skin and skin structure infections. Poster presentation at the European congress of clinical microbiology and infectious diseases Helsinki Finland May 1619 2009."},{"key":"e_1_2_1_60_2","unstructured":"CoreyGR WilcoxM. TalbotGH BaculikT. ThyeDA.CANVAS\u20101: randomized double\u2010blinded phase 3 study (P903\u201306) of the efficacy and safety of ceftaroline vs. vancomycin plus aztreonam in complicated skin and skin structure infections (cSSSI). Poster presentation at the 48th interscience conference on antimicrobial agents and chemotherapy\u201046th annual meeting of the Infectious Diseases Society of America Washington DC October 2528 2008."},{"key":"e_1_2_1_61_2","unstructured":"U.S. National Institutes of Health.ClinicalTrials.gov. Available fromhttp:clinicaltrials.govct2resultsterm ceftaroline. Accessed November 23 2009."},{"key":"e_1_2_1_62_2","doi-asserted-by":"crossref","unstructured":"EckburgP. FriedlandHD LeeJ. LlorensL. CritchleyIA ThyeDA.FOCUS 1 and 2: randomized double\u2010blinded multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community\u2010acquired pneumonia (CAP). Poster presentation at the 49th interscience conference on antimicrobial agents and chemotherapy San Francisco CA September 1215 2009.","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A2273"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.30.4.375","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.30.4.375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:23:27Z","timestamp":1761049407000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.30.4.375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1592\/phco.30.4.375"],"URL":"https:\/\/doi.org\/10.1592\/phco.30.4.375","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}